MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics


MiNK Therapeutics, Inc. (INKT): $1.67

0.31 (+22.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INKT Stock Price Chart Interactive Chart >

Price chart for INKT

INKT Price/Volume Stats

Current price $1.67 52-week high $22.16
Prev. close $1.36 52-week low $1.20
Day low $1.44 Volume 28,100
Day high $1.69 Avg. volume 71,336
50-day MA $2.15 Dividend yield N/A
200-day MA $0.00 Market Cap 56.05M

MiNK Therapeutics, Inc. (INKT) Company Bio


MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.


INKT Latest News Stream


Event/Time News Detail
Loading, please wait...

INKT Latest Social Stream


Loading social stream, please wait...

View Full INKT Social Stream

Latest INKT News From Around the Web

Below are the latest news stories about MiNK Therapeutics Inc that investors may wish to consider to help them evaluate INKT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning, investor!

William White on InvestorPlace | January 28, 2022

Could The MiNK Therapeutics, Inc. (NASDAQ:INKT) Ownership Structure Tell Us Something Useful?

Every investor in MiNK Therapeutics, Inc. ( NASDAQ:INKT ) should be aware of the most powerful shareholder groups...

Yahoo | January 15, 2022

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27th, 2022, at 12:00 pm

Yahoo | January 12, 2022

Agenus COO resigns to lead subsidiary MiNK Therapeutics (NASDAQ:INKT)

Agenus (AGEN) announced that Dr. Jennifer Buell, its President and Chief Operating Officer, resigned from her position at the company to become President and Chief Executive Officer at

Seeking Alpha | January 7, 2022

Sorrento Therapeutics (NASDAQ:SRNE) and MiNK Therapeutics (NASDAQ:INKT) Head to Head Review

Sorrento Therapeutics (NASDAQ:SRNE) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Sorrento Therapeutics and MiNK Therapeutics net margins, return on equity and []

Transcript Daily | December 23, 2021

Read More 'INKT' Stories Here

INKT Price Returns

1-mo -25.45%
3-mo -35.52%
6-mo -87.42%
1-year N/A
3-year N/A
5-year N/A
YTD -62.56%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7226 seconds.